General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-01 | 2024-06 | 10.57 | N/A | N/A | N/A |
2024-05-02 | 2024-03 | 10.2 | 9.55 | -0.65 | -6.37% |
2024-02-02 | 2023-12 | 10.43 | 11.86 | 1.43 | 13.71% |
2023-11-02 | 2023-09 | 10.8 | 11.59 | 0.79 | 7.31% |
2023-08-03 | 2023-06 | 9.92 | 10.24 | 0.32 | 3.23% |
2023-05-04 | 2023-03 | 9.25 | 10.09 | 0.84 | 9.08% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-15 | Cantor Fitzgerald | Upgrade | Neutral | Neutral |
2023-10-11 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-09-20 | Cantor Fitzgerald | Upgrade | Neutral | Neutral |
2023-09-14 | WestPark Capital | Upgrade | Hold | |
2023-09-14 | Argus Research | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-06-04 | BASSLER BONNIE L | Director | 1.38K | Sale |
2024-05-27 | BROWN MICHAEL S | Director | 12.54K | Sale |
2024-06-09 | LAROSA JOSEPH J | General Counsel | 0.00 | Stock Gift |
2024-06-02 | MCCOURT MARION E | Officer | 13.11K | Sale |
2024-03-13 | MURPHY ANDREW J | Officer | 52.62K | Sale |
2024-06-02 | RYAN ARTHUR F | Director | 17.98K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | FMR, LLC | 9.17M | 6.59B | 8.45% |
2023-06-29 | Blackrock Inc. | 9.09M | 6.53B | 8.37% |
2023-06-29 | Vanguard Group Inc | 8.86M | 6.36B | 8.16% |
2023-06-29 | JP Morgan Chase & Company | 6.54M | 4.70B | 6.03% |
2023-06-29 | Capital World Investors | 5.55M | 3.99B | 5.11% |
2023-06-29 | State Street Corporation | 4.99M | 3.59B | 4.60% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Growth Fund Of America Inc | 3.26M | 2.34B | 3.00% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.20M | 2.30B | 2.95% |
2023-08-30 | Fidelity Contrafund Inc | 2.65M | 2.19B | 2.44% |
2023-06-29 | Vanguard 500 Index Fund | 2.57M | 1.85B | 2.37% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 1.83M | 1.51B | 1.68% |
2023-06-29 | Dodge & Cox Stock Fund | 1.55M | 1.11B | 1.43% |
$REGN
Bernstein initiates Regeneron as outperform
Bernstein said the biotechnology company is “writing the next chapter of growth.
“We initiate coverage on Regeneron with an Outperform rating and $1,125 price target.”
Fire all executive levels at the hyper corrupt FDA.
750+ sp tomorrow
$REGN Regeneron's (REGN) Wet AMD Study on High Dose Eylea Meets Goal
Sorrento therapeutics has a better option !
Smaller doses ! In phase 11 in the uK now .
$SRNE
$REGN It is our time! Going higher, much higher!
$REGN Numerous upgrades!! Ripping
$REGN Beats on all levels! Going higher
Can’t be happier with companies performance and growth opportunity
Nice EPS beat of 12% https://finance.yahoo.com/news/regeneron-regn-tops-q1-earnings-114511589.html
Pipeline and fundamentals are great... now let’s save some lives and get the heck outta this madness.
The fact this is not up huge shows how slow most investors are...